Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 9;107(8):1227-32.
doi: 10.1038/bjc.2012.327. Epub 2012 Sep 11.

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies

G Procopio  1 , E Verzoni, R Iacovelli, D Biasoni, I Testa, L Porcu, F De Braud
Affiliations

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies

G Procopio et al. Br J Cancer. .

Abstract

Background: The most important prognostic factors for survival in patients with metastatic renal cell carcinoma (mRCC) were evaluated in the era of cytokine therapy, and only recently were revalidating in patients receiving targeted therapies (TTs).

Methods: Clinical data for consecutive patients with mRCC who received TTs were retrieved from the database of Istituto Nazionale dei Tumori of Milan. Variables with a significant association with overall survival (OS) were estimated by proportional hazard regression, and a backward stepwise multivariate analysis identified the independent prognostic factors.

Results: Data for 336 consecutive patients treated with TTs for RCC during the period 2004-2011 were evaluated. According to the Motzer classification, 32% patients were low risk, 48% were intermediate risk and 20% were poor risk. One hundred and sixty-seven (49.7%) patients received one TT, 116 (34.5%) received a second-line TT, 42 (12.5%) a third-line TT and 11 (3.3%) patients received a fourth-line TT. The median OS was 24 months (95% CI 20.0, 27.0) and the 5-year OS rate was 24.6% (95% CI 18.7, 30.8%). In the uni- and multivariate analysis Motzer risk classification, Fuhrman grade and previous cytokine therapy were identified as independent prognostic factors (P<0.01).

Conclusion: The Motzer classification was confirmed as an independent prognostic factor for OS in patients with mRCC receiving TTs. Additionally, Fuhrman grade and previous cytokine therapy were independent prognostic factors for clinical outcome.

PubMed Disclaimer

Conflict of interest statement

Giuseppe Procopio received consultant fees and took part in advisory boards for Bayer Health Care, Pfizer, Novartis, GlaxoSmithKline. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overall survival in patients with metastatic renal cell carcinoma receiving targeted therapies.
Figure 2
Figure 2
Overall survival with sorafenib and sunitinib compared with other therapies in patients with metastatic renal cell carcinoma.
Figure 3
Figure 3
Overall survival in patients with metastatic renal cell carcinoma receiving targeted therapies stratified according to (A) Motzer classification, (B) Eastern Cooperative Oncology Group performance status (ECOG PS), (C) nephrectomy status and (D) previous cytokine therapy.
See this image and copyright information in PMC

References

    1. Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K, Escudier B (2011) Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 22(8): 1812–1823 - PubMed
    1. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110(3): 543–550 - PubMed
    1. Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 85(1): 60–66 - PubMed
    1. Dixon JR (1998) The international conference on harmonization good clinical practice guideline. Qual Assur 6(2): 65–74 - PubMed
    1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2): 125–134 - PubMed

Publication types

MeSH terms